Skip to main content
Evidence Snapshot

Misshapen-like kinase 1

CHEMBL5518 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5518
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Misshapen-like kinase 1 as ChEMBL target CHEMBL5518, mapped to UniProt Q8N4C8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Misshapen-like kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5518
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8N4C8
Misshapen-like kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Misshapen-like kinase 1 matters

As of 2026-09-14

Misshapen-like kinase 1 is reviewed as Misshapen-like kinase 1 (UniProt Q8N4C8); the current evidence base includes 19 approved drugs, 1759 compounds, and 322 assays, with lead potency reaching pChEMBL 9.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 19 approved drugs, 1759 compounds, and 322 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine
19 approved pChEMBL 9.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Misshapen-like kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8N4C8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1759
Total Compounds
322
Total Assays
19
Approved Drugs
IC50: 58.0, KI: 663.0, KD: 209.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 9.6 IC50 —
No preferred name
CHEMBL388978
 9.0 Kd —
No preferred name
CHEMBL379975
 8.9 Ki —
No preferred name
CHEMBL4746566
 8.9 IC50 —
No preferred name
CHEMBL1986943
 8.5 Ki —

Approved Drugs

Structure Compound First Approval
NERATINIB
CHEMBL180022
 2017
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
AXITINIB
CHEMBL1289926
 2012
SUNITINIB
CHEMBL535
 2006
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5518